Cognitive disorders in people living with HIV disease

doi:10.1017/CBO9780511543586.003

2 - Cognitive disorders in people living with HIV disease

Published online by Cambridge University Press: 06 August 2009

Julie D. Maggi M.D., M.sc. ,

Sean B. Rourke Ph.D. and

Mark Halman M.D.

Edited by

Kenneth Citron ,

Marie Josée Brouillette and

Alexandra Beckett

Show author details

Julie D. Maggi M.D., M.sc.: Affiliation:
Assistant Professor of Psychiatry, University of Toronto, Staff Psychiatrist, Mental Health Services, St. Michael's Hospital, Toronto, Canada
Sean B. Rourke Ph.D.: Affiliation:
Associate Professor of Psychiatry, University of Toronto, Director of Research, Mental Health Services, St. Michael's Hospital, Toronto, Canada
Mark Halman M.D.: Affiliation:
Assistant Professor of Psychiatry, University of Toronto, Director, HIV Psychiatry Program, St. Michael's Hospital, Toronto, Canada
Marie Josée Brouillette: Affiliation:
McGill University, Montréal
Alexandra Beckett: Affiliation:
Harvard University, Massachusetts

Book contents

Get access

Summary

Introduction

Cognitive complaints are common in HIV disease. Over the course of the HIV epidemic, researchers have come to understand a great deal about cognitive difficulties associated with HIV disease. HIV enters the central nervous system shortly after infection and has a predilection for subcortical brain areas. As the disease progresses, proinflammatory neurotoxins that cause cell injury and cell dysfunction are released. As a result, many people with HIV disease begin to experience difficulties in cognitive functioning. Given the morbidity associated with cognitive disorders for people living with HIV disease, it is essential that practitioners accurately assess changes in mental status. Diagnosis must be grounded in a thorough history and careful psychiatric, mental status, neurologic examination, and where available, neuropsychological examination. Assessment must consider the patient's clinical stage as well as laboratory markers of immune dysfunction and viral burden.

What causes the cognitive dysfunction associated with HIV infection?

The pathophysiologic mechanism that leads to cognitive dysfunction is unclear, but is thought to be related to HIV replication in the brain, activation of HIV-infected brain microglial cells, liberation of inflammatory neurotoxins (e.g., cytokines, Tumour Necrosis Factor), and impairment in natural host repair mechanisms, ultimately resulting in a level of neuronal dysfunction, injury, or death. The areas most affected are the subcortical brain regions and the fronto-striatal circuitry (Cummings, 1990; Parks et al., 1993; Wesselingh et al., 1994; Tyor et al., 1995; Grant and Adams, 1996; Masliah et al., 1997; Tan and Guiloff, 1998).

Type: Chapter
Information: HIV and Psychiatry
Training and Resource Manual
, pp. 30 - 55

DOI: https://doi.org/10.1017/CBO9780511543586.003 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Albert, S. M., Marder, K., Dooneief, G.et al. Neuropsychologic impairment in early HIV infection: A risk factor for work disability. Archives of Neurology, 52(5) (1995): 525–30.Google Scholar

Albert, S. M., Weber, C., Todak, G.et al. An observed performance test of medication management ability in HIV: relation to neuropsychological status and medication adherence outcomes. Aids and Behavior, 3(2)(1999): 121–8.Google Scholar

American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Neurology, 41(6)(1991): 778–85.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 4thedn text revised. Washington, DC: American Psychiatric Association, 2000.

Aweeka, F., Jayewardene, A., Staprans, S.et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 20 (1999): 39–43.Google Scholar

Breitbart, W., Rosenfeld, B., Kaim, M. and Funesti-Esch, J.A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine, 161(3)(2001): 411–20.Google Scholar

Brew, B. J., Brown, S. J., Catalan, J. et al., Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (study CNAB 3001) (abstract no. 32192). 12th World AIDS Conference, Geneva, Switzerland, 1998.

Catz, S. L., Kelly, J. A., Bogart, L. M.et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatment for HIV disease. Health Psychology, 19(2) (2000): 124–133.Google Scholar

Chang, L., Ernst, T., Leonido-Yee, M.et al. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology, 52(1) (1999): 100–8.Google Scholar

Cohen, R. A., Boland, R., Paul, R.et al. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS, 15(3) (2001): 341–5.Google Scholar

Cummings, J. L.Subcortical Dementia. New York: Oxford University Press, 1990.

Dore, G. J., Correll, P. K., Li, Y.et al. Changes in AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS, 13(1999): 1249–53.Google Scholar

Ellis, R. J., Deutsch, R., Heaton, R. K.et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. Archives of Neurology, 54(1997): 416–24.Google Scholar

Ellis, R. J., Moore, D. J., Childers, M. E.et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Archives of Neurology, 59(6) (2002): 923–8.Google Scholar

Ferrando, S., Gorp, W., McElhiney, M.et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS, 12(8) (1998): F65–70.Google Scholar

Filippi, C. G., Sze, G., Farber, S. J.et al. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology, 206(1998): 491–8.Google Scholar

Galgani, S., Balestra, P., Tozzi, V.et al. Comparison of efficacy of different antiretroviral regimens on neuropsychological performance in HIV-1 patients (abstract). Journal of NeuroVirology, 4(1998): 350.Google Scholar

Grant, I. and Adams, K. M. (eds.) Neuropsychological Assessment of Neuropsychiatric Disorders. New York: Oxford University Press, 1996.

Grant, I. and Martin, A.Neuropsychology of HIV infection. New York: Oxford University Press, 1994.

Heaton, R. K., and Grant, I. Neurobehavioral Progress Report/Preliminary Studies (research plan present to NIMH, Office on AIDS), Grant, I., ed. San Diego, CA: HIV Neurobehavioral Research Center, 1995.

Heaton, R. K., Marcotte, T. D., White, D. A.et al. Nature and vocational significance or neuropsychological impairment associated with HIV infection. Clinical Neuropsychologist, 10 (1996): 1–14.Google Scholar

Heaton, R. K., Velin, R. A., McCutchan, J. A.et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group, HIV Neurobehavioral Research Center. Psychosomatic Medicine, 56(1)(1994): 8–17.Google Scholar

Hriso, E., Kuhn, T., Masdeu, J. C. and Grundman, M.Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. American Journal of Psychiatry, 148(11)(1991): 1558–61.Google Scholar

Kaplan, R. M., Anderson, J. P., Patterson, T. L.et al. Validity of the quality of well-being scale for persons with human immunodeficiency virus infection. HNRC Group, HIV Neurobehavioral Research Center. Psychosomatic Medicine, 57(2) (1995): 138–47.Google Scholar

Letendre, S., Ellis, R., Heaton, R. K.et al. Change in CSF RNA level correlates with the effects of antiretroviral therapy on HIV-1 associated neurocognitive disorder (abstract no. 32198). Journal of NeuroVirology, 4(1998): 357.Google Scholar

Maggi, J. D. and Halman, M. H.The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Canadian Journal of Psychiatry, 46(4) (2001): 359–62.Google Scholar

Marder, K., Albert, S. M., McDermott, M. and the DANA Consortium on therapy for HIV dementia and related disorders. Prospective study of neurocognitive impairment in HIV (DANA cohort): dementia and mortality outcomes. Journal of NeuroVirology, 4 (1998): 358.Google Scholar

Martin, E. M., Pitrak, D. L., Pursell, K. J.et al. Information processing and antiretroviral therapy in HIV-1 infection. Journal of the International Neuropsychological Society, 4(1998): 329–35.Google Scholar

Masliah, E., Heaton, R. K., Marcotte, T. D.et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Annals of Neurology, 42(1997): 963–72.Google Scholar

McArthur, J. C., Hoover, D. R., Bacellar, H.et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology, 43(11) (1993): 2245–52.Google Scholar

McArthur, J. C., McClernon, D. R., Cronin, M. F.et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology, 42(5) (1997): 689–98Google Scholar

Moog, C., Kuntz-Simon, G., Caussin-Schwemling, C. and Obert, G.Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. Journal of General Virology, 77(1996): 1993–9.Google Scholar

Neuenburg, J. K., Brodt, H. R., Herndier, B. G.et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(2) (2002): 171–7.Google Scholar

Parks, R. W., Zec, R. F. and Wilson, R. S. (eds.). Neuropsychology of Alzheimer's Disease and Other Dementias. New York: Oxford University Press, 1993.

Paterson, D. L., Swindells, S., Mohr, J. and Brester, M.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1) (2000): 21–30.Google Scholar

Power, C., Selnes, O. A., Grim, J. A., and McArthur, J. C.HIV Dementia Scale: a rapid screening test. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 8(3) (1995): 273–8.Google Scholar

Price, R. W. and Brew, B. J.The AIDS dementia complex. Journal of Infectious Diseases, 158(1992): 1079–83.Google Scholar

Rourke, S. B., Bassel, C. and Halman, M. H.Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. Journal of Clinical and Experimental Neuropsychology, 21 (1999a): 737–56.Google Scholar

Rourke, S. B., Bassel, C. and Halman, M. H.Neuropsychiatric correlates of memory-metamemory dissociations in HIV-1 infection. Journal of Clinical and Experimental Neuropsychology, 21(1999b): 757–68.Google Scholar

Sacktor, N. C., Lyles, R. H., Skolasky, R. L.et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology, 52(8) (1999): 1640–7.Google Scholar

Schmitt, F. A., Bigley, J. W., McKinnis, R.et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine, 319(24) (1988): 1573–8.Google Scholar

Sidtis, J. J., Gatsonis, C., Price, R. W.et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Annals of Neurology, 33(4)(1993): 343–9.Google Scholar

Simon, G., Moog, C. and Obert, G.. Valproic acid reduces the intracellular level of glutathione and stimulates human immunodeficiency virus. Chemico-Biological Interactions, 91 (1994): 111–21.Google Scholar

Smith, C. A., Gorp, W. G., Ryan, E. R.et al. (2003). Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV Dementia Scale. Journal of AIDS, 33(1) (2003): 116–18.Google Scholar

Stankoff, B., Calves, V., Suarez, S.et al. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment. European Journal of Neurology, 6(6) (1999): 669–75.Google Scholar

Tan, S. V. and Guiloff, R. J.Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS [comment]. Journal of Neurology, Neurosurgery and Psychiatry, 65(1) (1998): 23–8.Google Scholar

Tozzi, V., Balestra, P., Galgani, S.et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS, 13(14) (1999): 1889–97.Google Scholar

Tyor, W. R., Wesselingh, S. L., Griffin, J. W.et al. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 9(1995): 379–88.Google Scholar

Wesselingh, S. L., Glass, J., McArthur, J. C.et al. Cytokine dysregulation in HIV-associated neurological disease. Advances in Neuroimmunology, 4(3) (1994): 199–206.Google Scholar

White, J. L., Darko, D. F., Brown, S. J.et al. Early central nervous system response to HIV infection: sleep distortion and cognitive-motor decrements. AIDS, 9(9) (1995): 1043–50.Google Scholar

Witvrouw, M., Schmit, J. C., Remoortel, B.et al. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Research and Human Retroviruses, 13 (1997): 187–92.Google Scholar